Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial

Autor: Florence Ouedraogo, Reshma Kailath, Amy Flaxman, Andres Noe, Rachidatou Soma, Fernando Ramos Lopez, Katie J. Ewer, Eli Rouamba, Umesh Shaligram, Jenny M. Reimer, Toussaint Rouamba, Federica Cappuccini, Ousmane Traore, Athanase M Some, Prisca Yameogo, Matthew Cairns, M Datoo, Daniel Valia, Benedict O. Orindi, Seydou Sawadogo, Sean C. Elias, Karim Derra, D Bellamy, Faizatou Sorgho, Magloire H Natama, Adrian V. S. Hill, E Mukhopadhyay, Hermann Sorgho, Innocent Valea, Alison M. Lawrie, Moubarak Tegneri, Rachel Roberts, Gregory M. Glenn, Halidou Tinto, Louis Fries, Nicola Williams
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
medicine.medical_specialty
medicine.medical_treatment
Population
Protozoan Proteins
Antibodies
Protozoan
030204 cardiovascular system & hematology
law.invention
03 medical and health sciences
0302 clinical medicine
Immunogenicity
Vaccine
Randomized controlled trial
Adjuvants
Immunologic
Double-Blind Method
law
Internal medicine
Burkina Faso
Malaria Vaccines
parasitic diseases
medicine
Humans
030212 general & internal medicine
Vaccines
Virus-Like Particle
Malaria
Falciparum
education
Proportional Hazards Models
education.field_of_study
Hepatitis B Surface Antigens
business.industry
Malaria vaccine
Infant
General Medicine
Saponins
Sciences bio-médicales et agricoles
Vaccine efficacy
medicine.disease
Malaria
Clinical trial
Vaccination
Treatment Outcome
Nanoparticles
Female
business
Adjuvant
Zdroj: Lancet, 397 (10287
ISSN: 0140-6736
Popis: Stalled progress in controlling Plasmodium falciparum malaria highlights the need for an effective and deployable vaccine. RTS,S/AS01, the most effective malaria vaccine candidate to date, demonstrated 56% efficacy over 12 months in African children. We therefore assessed a new candidate vaccine for safety and efficacy.
info:eu-repo/semantics/published
Databáze: OpenAIRE
Externí odkaz: